JP2013536828A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013536828A5 JP2013536828A5 JP2013526490A JP2013526490A JP2013536828A5 JP 2013536828 A5 JP2013536828 A5 JP 2013536828A5 JP 2013526490 A JP2013526490 A JP 2013526490A JP 2013526490 A JP2013526490 A JP 2013526490A JP 2013536828 A5 JP2013536828 A5 JP 2013536828A5
- Authority
- JP
- Japan
- Prior art keywords
- transdermal therapeutic
- therapeutic system
- solid transdermal
- matrix
- protective film
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000011159 matrix material Substances 0.000 claims description 17
- 230000001225 therapeutic effect Effects 0.000 claims description 13
- 239000007787 solid Substances 0.000 claims description 12
- 239000004480 active ingredient Substances 0.000 claims description 9
- 230000001681 protective effect Effects 0.000 claims description 9
- 229920000642 polymer Polymers 0.000 claims description 6
- 238000002425 crystallisation Methods 0.000 claims description 3
- 230000008025 crystallization Effects 0.000 claims description 3
- 239000002270 dispersing agent Substances 0.000 claims description 3
- 238000004090 dissolution Methods 0.000 claims description 3
- 239000003112 inhibitor Substances 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 3
- SIGSPDASOTUPFS-XUDSTZEESA-N gestodene Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](C=C4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 SIGSPDASOTUPFS-XUDSTZEESA-N 0.000 claims description 2
- 229960005352 gestodene Drugs 0.000 claims description 2
- 239000010410 layer Substances 0.000 claims 4
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 claims 2
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 claims 2
- 239000004743 Polypropylene Substances 0.000 claims 2
- 239000006096 absorbing agent Substances 0.000 claims 2
- 239000012790 adhesive layer Substances 0.000 claims 2
- 229960002568 ethinylestradiol Drugs 0.000 claims 2
- -1 polyethylene terephthalate Polymers 0.000 claims 2
- 229920000139 polyethylene terephthalate Polymers 0.000 claims 2
- 239000005020 polyethylene terephthalate Substances 0.000 claims 2
- 229920001155 polypropylene Polymers 0.000 claims 2
- 229920001296 polysiloxane Polymers 0.000 claims 2
- 229920002367 Polyisobutene Polymers 0.000 claims 1
- XVAMCHGMPYWHNL-UHFFFAOYSA-N bemotrizinol Chemical group OC1=CC(OCC(CC)CCCC)=CC=C1C1=NC(C=2C=CC(OC)=CC=2)=NC(C=2C(=CC(OCC(CC)CCCC)=CC=2)O)=N1 XVAMCHGMPYWHNL-UHFFFAOYSA-N 0.000 claims 1
- 229960004101 bemotrizinol Drugs 0.000 claims 1
- 239000004811 fluoropolymer Substances 0.000 claims 1
- 229920002313 fluoropolymer Polymers 0.000 claims 1
- 239000004446 fluoropolymer coating Substances 0.000 claims 1
- 229920000728 polyester Polymers 0.000 claims 1
- 239000002356 single layer Substances 0.000 claims 1
- 150000002148 esters Chemical class 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102010040299A DE102010040299A1 (de) | 2010-09-06 | 2010-09-06 | Transdermale therapeutische Systeme mit kristallisationsinhibierender Schutzfolie (Release Liner) |
| DE102010040299.0 | 2010-09-06 | ||
| PCT/EP2011/065204 WO2012031985A1 (de) | 2010-09-06 | 2011-09-02 | Transdermale therapeutische systeme mit kristallisationsinhibierender schutzfolie (release liner) |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016161929A Division JP2016216500A (ja) | 2010-09-06 | 2016-08-22 | 結晶化を阻害する保護フィルムを有する経皮治療システム（剥離ライナー |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013536828A JP2013536828A (ja) | 2013-09-26 |
| JP2013536828A5 true JP2013536828A5 (enExample) | 2017-02-02 |
| JP6104800B2 JP6104800B2 (ja) | 2017-03-29 |
Family
ID=44653285
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013526490A Expired - Fee Related JP6104800B2 (ja) | 2010-09-06 | 2011-09-02 | 結晶化を阻害する保護フィルムを有する経皮治療システム（剥離ライナー） |
| JP2016161929A Pending JP2016216500A (ja) | 2010-09-06 | 2016-08-22 | 結晶化を阻害する保護フィルムを有する経皮治療システム（剥離ライナー |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016161929A Pending JP2016216500A (ja) | 2010-09-06 | 2016-08-22 | 結晶化を阻害する保護フィルムを有する経皮治療システム（剥離ライナー |
Country Status (33)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI630208B (zh) | 2008-12-08 | 2018-07-21 | 歐陸斯迪公司 | 二氫羥戊甲嗎啡 |
| GB201309654D0 (en) | 2013-05-30 | 2013-07-17 | Euro Celtique Sa | Method |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH674618A5 (enExample) * | 1987-04-02 | 1990-06-29 | Ciba Geigy Ag | |
| DE58909570D1 (de) | 1988-10-27 | 1996-02-22 | Schering Ag | Mittel zur transdermalen applikation enthaltend gestoden |
| MX9101787A (es) | 1990-10-29 | 1992-06-05 | Alza Corp | Formulaciones,metodos y dispositivos anticonceptivos transdermicos |
| US5512292A (en) | 1990-10-29 | 1996-04-30 | Alza Corporation | Transdermal contraceptive formulations methods and devices |
| DE4210711A1 (de) | 1991-10-31 | 1993-05-06 | Schering Ag Berlin Und Bergkamen, 1000 Berlin, De | Transdermale therapeutische systeme mit kristallisationsinhibitoren |
| DE4336557C2 (de) | 1993-05-06 | 1997-07-17 | Lohmann Therapie Syst Lts | Estradiolhaltiges transdermales therapeutisches System, Verfahren zu seiner Herstellung und seine Verwendung |
| DE4405899A1 (de) * | 1994-02-18 | 1995-08-24 | Schering Ag | Mittel zur transdermalen Applikation enthaltend Desogestrel |
| DE4405898A1 (de) | 1994-02-18 | 1995-08-24 | Schering Ag | Transdermale therapeutische Systeme enthaltend Sexualsteroide |
| US5762956A (en) | 1996-04-24 | 1998-06-09 | Rutgers, The State University Of New Jersey | Transdermal contraceptive delivery system and process |
| DE19629468A1 (de) * | 1996-07-11 | 1998-01-15 | Schering Ag | Transdermale therapeutische Systeme |
| DE19827732A1 (de) * | 1998-06-22 | 1999-12-23 | Rottapharm Bv | Transdermales System vom Matrix-Typ zur Abgabe von Wirkstoffen mit einer hohen Abgaberate von Steroid-Hormonen und die Verwendung eines derartigen Systems zur Hormonersatztherapie |
| DE19906152B4 (de) | 1999-02-10 | 2005-02-10 | Jenapharm Gmbh & Co. Kg | Wirkstoffhaltige Laminate für Transdermalsysteme |
| NZ518723A (en) | 1999-11-24 | 2004-04-30 | Agile Therapeutics Inc | Improved transdermal contraceptive delivery system and process |
| DE10053375C1 (de) * | 2000-10-27 | 2002-01-24 | Lohmann Therapie Syst Lts | Transdermale therapeutische Systeme mit lichtempfindlichen Wirkstoffen |
| AU2002235155A1 (en) | 2000-12-05 | 2002-06-18 | Noven Pharmaceuticals, Inc. | Crystallization inhibition of drugs in transdermal drug delivery systems |
| EP1216699A1 (de) | 2000-12-21 | 2002-06-26 | Schering Aktiengesellschaft | Transdermalsystem enthaltend ein hochpotentes Gestagen |
| US20030165547A1 (en) * | 2001-05-18 | 2003-09-04 | Elisabeth Picard-Lesboueyries | Cosmetic uses of 3beta-acetoxy-7-oxo-DHEA |
| DE10261696A1 (de) | 2002-12-30 | 2004-07-15 | Schwarz Pharma Ag | Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base |
| ME00147B (me) * | 2003-02-21 | 2010-10-10 | Schering Ag | Uv-stabilni transdermalni flasteri |
| UA89766C2 (en) * | 2003-12-12 | 2010-03-10 | Байер Шеринг Фарма Акциенгезельшафт | Transdermal delivery system of gestodene |
| US8668925B2 (en) * | 2003-12-12 | 2014-03-11 | Bayer Intellectual Property Gmbh | Transdermal delivery of hormones without the need of penetration enhancers |
| JP4965263B2 (ja) | 2003-12-12 | 2012-07-04 | バイエル ファーマ アクチエンゲゼルシャフト | 浸透増強剤を必要としないホルモンの経皮送達 |
| MX2007004315A (es) * | 2004-10-08 | 2008-03-11 | Noven Pharma | Dispositivo para suministro transdermico de farmaco que incluye un respaldo oclusivo. |
| DE102004062182B4 (de) | 2004-12-20 | 2007-06-06 | Bayer Schering Pharma Ag | Transdermales Pflaster mit Progesteron A-Spezifische Liganden (PRASL) als Wirkstoff |
| US8962013B2 (en) * | 2005-05-02 | 2015-02-24 | Bayer Intellectual Property Gmbh | Multi-layered transdermal system with triazine UV absorber |
| DE102005050729A1 (de) | 2005-10-19 | 2007-04-26 | Schering Ag | Verfahren zur präventiven bedarfsweisen hormonalen Kontrazeption |
| AU2009302853B2 (en) * | 2008-10-06 | 2014-09-11 | Mylan Technologies, Inc. | Amorphous rotigotine transdermal system |
-
2010
- 2010-09-06 DE DE102010040299A patent/DE102010040299A1/de not_active Withdrawn
-
2011
- 2011-02-09 UA UAA201304320A patent/UA110217C2/ru unknown
- 2011-09-02 CA CA2810103A patent/CA2810103C/en active Active
- 2011-09-02 SG SG10201506927TA patent/SG10201506927TA/en unknown
- 2011-09-02 NZ NZ607630A patent/NZ607630A/en not_active IP Right Cessation
- 2011-09-02 JP JP2013526490A patent/JP6104800B2/ja not_active Expired - Fee Related
- 2011-09-02 AP AP2013006787A patent/AP3586A/xx active
- 2011-09-02 CU CU20130031A patent/CU24172B1/es active IP Right Grant
- 2011-09-02 MA MA35706A patent/MA34581B1/fr unknown
- 2011-09-02 MY MYPI2013700339A patent/MY162768A/en unknown
- 2011-09-02 BR BR112013005305A patent/BR112013005305A2/pt not_active Application Discontinuation
- 2011-09-02 EP EP11757808.8A patent/EP2613771A1/de not_active Withdrawn
- 2011-09-02 KR KR1020137008726A patent/KR20130114127A/ko not_active Ceased
- 2011-09-02 WO PCT/EP2011/065204 patent/WO2012031985A1/de not_active Ceased
- 2011-09-02 PE PE2013000383A patent/PE20131138A1/es not_active Application Discontinuation
- 2011-09-02 MX MX2013002602A patent/MX2013002602A/es active IP Right Grant
- 2011-09-02 AU AU2011298892A patent/AU2011298892B2/en not_active Ceased
- 2011-09-02 SG SG2013013453A patent/SG187941A1/en unknown
- 2011-09-02 PE PE2017001638A patent/PE20180198A1/es not_active Application Discontinuation
- 2011-09-02 EA EA201390246A patent/EA032575B1/ru not_active IP Right Cessation
- 2011-09-02 CN CN201180042701.6A patent/CN103079549B/zh not_active Expired - Fee Related
- 2011-09-02 PH PH1/2013/500429A patent/PH12013500429A1/en unknown
- 2011-09-05 UY UY0001033590A patent/UY33590A/es unknown
- 2011-09-06 US US13/225,660 patent/US8557279B2/en not_active Expired - Fee Related
- 2011-09-06 AR ARP110103250A patent/AR082907A1/es unknown
- 2011-09-06 TW TW100132149A patent/TWI576245B/zh not_active IP Right Cessation
-
2013
- 2013-02-22 ZA ZA2013/01389A patent/ZA201301389B/en unknown
- 2013-02-28 IL IL224980A patent/IL224980A/en not_active IP Right Cessation
- 2013-03-05 TN TNP2013000087A patent/TN2013000087A1/fr unknown
- 2013-03-06 CO CO13045117A patent/CO6690753A2/es unknown
- 2013-03-06 CR CR20130098A patent/CR20130098A/es unknown
- 2013-03-06 GT GT201300062A patent/GT201300062A/es unknown
- 2013-03-06 CL CL2013000636A patent/CL2013000636A1/es unknown
- 2013-03-06 DO DO2013000053A patent/DOP2013000053A/es unknown
- 2013-03-06 EC ECSP13012477 patent/ECSP13012477A/es unknown
- 2013-09-17 US US14/028,990 patent/US9060955B2/en not_active Expired - Fee Related
-
2016
- 2016-08-22 JP JP2016161929A patent/JP2016216500A/ja active Pending
-
2017
- 2017-03-13 IL IL251124A patent/IL251124B/en active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014065727A5 (enExample) | ||
| ES2528650T3 (es) | Sistema terapéutico transdérmico que comprende buprenorfina | |
| ES2299630T3 (es) | Emplastos para la profilaxis y/o el tratamiento de disfunciones o trastornos del crecimiento de las uñas. | |
| JP5658353B2 (ja) | 経皮吸収製剤 | |
| JP2016504368A5 (enExample) | ||
| JP2012504609A5 (enExample) | ||
| JP2015500329A5 (enExample) | ||
| JP2010521525A5 (enExample) | ||
| JP2010510260A5 (enExample) | ||
| EP2522339A3 (en) | Amorphous drug transdermal systems, manufacturing methods, and stabilization | |
| CA2861782C (en) | Transdermal therapeutic system with a low tendency to spontaneously crystallize | |
| RU2014111255A (ru) | Трансдермальная терапевтическая система для гидрохлорида 5-аминолевулиновой кислоты | |
| CN103096882A (zh) | 含有多奈哌齐的经皮吸收制剂 | |
| JP6556873B2 (ja) | 経皮吸収製剤 | |
| JP2016502989A5 (enExample) | ||
| EA201591124A1 (ru) | Трансдермальная система доставки | |
| JP2016522792A (ja) | リバスチグミンを含む、経皮薬物送達システム | |
| JP2004529890A5 (enExample) | ||
| CN106659702A (zh) | 透皮递送体系 | |
| JP2013536828A5 (enExample) | ||
| EP2457565A1 (de) | Transdermales therapeutisches System enthaltend Rotigotin | |
| ES2745154T3 (es) | Sistema de tratamiento transdérmico que contiene buprenorfina y un alfa-hidroxiácido | |
| ES2629063T3 (es) | Preparación de parche | |
| NZ607630A (en) | Transdermal therapeutic systems with crystallization-inhibiting protective film (release liner) | |
| CN107484412B (zh) | 含有罗匹尼罗的贴剂 |